Immune secrets of AML treatment revealed: new study paves way for smarter immunotherapies

NCT ID NCT06279572

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 22 times

Summary

This study collects blood and bone marrow samples from 80 adults with newly diagnosed acute myeloid leukemia (AML) who are receiving standard treatment with azacitidine and venetoclax. Researchers will analyze the immune profile of these samples to understand how the body responds to the therapy. The goal is to use this information to develop better immune-based treatments for AML in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    NOT_YET_RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic in Rochester

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.